Skip to content
Catalyst
PANSS positive subscale score

1 finding · 1 compound · by evidence strength. No dose is advised.

Fig. 2 PANSS positive subscale score1 compound outer ring on requestSelected PANSS positive subscale score · centre
×1.60
Labels
Measured outcomeInspector

PANSS positive subscale score

Findings drawn, by strength

1finding · 1 compound

  • Very limited1
Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

Compound lowersFindingsStrongest
1
Very limited

Not pooled · no summary effect · point at a mark · Tab, then the arrow keys

Reported to move it1 finding

  1. L-theanineMoved: lowersEvidence: Very limitedPaper: PMID 212085862011
    Who
    Chronic schizophrenia or schizoaffective disorder (DSM-IV); antipsychotic treatment continued in both arms as background; 8-week 2-center trial; PANSS 3-dimensional model
    Dose studied
    L-theanine 400 mg/d added to ongoing antipsychotic

    Compared with placebo, L-theanine augmentation was associated with reduction of anxiety (P = .015; measured by the HARS scale) and positive (P = .009) and general psychopathology (P < .001) scores (measured by the PANSS 3-dimensional model).”

    Quoted verbatim from L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.RCT · 8 weeksPermalink

How it is measured

Sum of the seven positive scale items (P1 to P7: delusions, conceptual disorganisation, hallucinatory behaviour, excitement, grandiosity, suspiciousness and hostility) of the PANSS (Kay, Fiszbein and Opler 1987), each rated 1 to 7, summed to 7 to 49; higher is worse.

Measured, with no finding

1 measurement

Show what was measuredHide what was measured
  • PANSS positive subscale score

    no effect

    Not recorded as a finding: Agentless passive covering four outcomes in one sentence and never naming the compound.

    No significant within- or between-group changes were observed for PANSS positive, SANS, CDRS, or MATRICS composite scores (Table 2).

    PMID 28289280 · one of two readings recorded this

Papers about it

As an endpoint2

Show the papersHide the papers
  • Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.

    Molecular psychiatry2018PMID 28289280Via: named in the paper, as read

  • L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.

    The Journal of clinical psychiatry2011PMID 21208586Via: named in the paper, as read

Newest

  • Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.

    Molecular psychiatry2018PMID 28289280As an endpoint

  • L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study.

    The Journal of clinical psychiatry2011PMID 21208586As an endpoint